Scholarlink

<p>Non-tuberculous mycobacteria are emerging pathogens with high intrinsic drug resistance. Among these, <i>Mycobacterium abscessus</i> is particularly refractory owing to its extensive array of resistance mechanisms. Here we introduce florfenicol amine (FF-NH<sub>2</sub>), a major metabolite of the antibiotic florfenicol, which acts as a prodrug with narrow-spectrum activity against <i>M.</i> <i>abscessus−chelonae</i> complex species. FF-NH<sub>2</sub> leverages intrinsic <i>M.</i> <i>abscessus</i> resistance conferred by the transcription factor WhiB7. It avoids WhiB7-dependent resistance mediated by the <i>O</i>-acetyltransferase Cat and is activated by the WhiB7-dependent <i>N</i>-acetyltransferase Eis2 in a prodrug fashion to generate the active translational inhibitor FF acetyl (FF-ac). FF-NH<sub>2</sub> induces Eis2 expression through WhiB7, creating a feed-forward bioactivation loop, which increases FF-ac accumulation and antimicrobial action. FF-NH<sub>2</sub> displays antiresistance properties, can synergize with other antibiotics and mitigates toxicity linked to mammalian mitochondrial ribosome inhibition. Importantly, FF-NH<sub>2</sub> demonstrated efficacy in a murine model of <i>M.</i> <i>abscessus</i> infection. These findings suggest intrinsic resistance can be exploited to develop safer and more effective treatments for this pathogen.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prodrug florfenicol amine is activated by intrinsic resistance to target Mycobacterium abscessus

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月30日

查看全文
  • Gregory A. Phelps,
  • Sinem Kurt,
  • Alexander R. Jenner,
  • Shelby M. Anderson,
  • Thalina D. Jayasinghe,
  • Elizabeth C. Griffith,
  • Carl W. Thompson,
  • Lei Yang,
  • Basil Wicki,
  • Frederick K. Bright,
  • Victoria Loudon,
  • William C. Wright,
  • Ashish Srivastava,
  • Amarinder Singh,
  • Bhargavi Thalluri,
  • Hyunseo Park,
  • Robin B. Lee,
  • Anna K. Wright,
  • Oliver Grant-Chapman,
  • Daryl K. Conner,
  • Brennen T. Troyer,
  • Amy Iverson,
  • Jason Ochoado,
  • Vishwajeeth R. Pagala,
  • Long Wu,
  • Stephanie Byrum,
  • Yingxue Fu,
  • Zu-Fei Yuan,
  • Anthony A. High,
  • Bettina Schulthess,
  • Jason W. Rosch,
  • Paul Geeleher,
  • Sven N. Hobbie,
  • Lucas Boeck,
  • Bernd Meibohm,
  • Andres Obregon-Henao,
  • Peter Sander,
  • Richard E. Lee

摘要

Non-tuberculous mycobacteria are emerging pathogens with high intrinsic drug resistance. Among these, Mycobacterium abscessus is particularly refractory owing to its extensive array of resistance mechanisms. Here we introduce florfenicol amine (FF-NH2), a major metabolite of the antibiotic florfenicol, which acts as a prodrug with narrow-spectrum activity against M. abscessus−chelonae complex species. FF-NH2 leverages intrinsic M. abscessus resistance conferred by the transcription factor WhiB7. It avoids WhiB7-dependent resistance mediated by the O-acetyltransferase Cat and is activated by the WhiB7-dependent N-acetyltransferase Eis2 in a prodrug fashion to generate the active translational inhibitor FF acetyl (FF-ac). FF-NH2 induces Eis2 expression through WhiB7, creating a feed-forward bioactivation loop, which increases FF-ac accumulation and antimicrobial action. FF-NH2 displays antiresistance properties, can synergize with other antibiotics and mitigates toxicity linked to mammalian mitochondrial ribosome inhibition. Importantly, FF-NH2 demonstrated efficacy in a murine model of M. abscessus infection. These findings suggest intrinsic resistance can be exploited to develop safer and more effective treatments for this pathogen.